Migalastat
Migalastat
Migalastat (pronounced as mi-ga-las-tat) is a medication used for the treatment of Fabry disease, a rare genetic disorder. It is marketed under the brand name Galafold.
Etymology
The name "Migalastat" is derived from its chemical structure, which is a derivative of 1-deoxygalactonojirimycin. The "Miga-" prefix is a contraction of "mimetic galactose", referring to the drug's mechanism of action as a pharmacological chaperone that mimics the structure of the sugar galactose.
Usage
Migalastat is used to treat adults with Fabry disease who have a specific genetic mutation that is responsive to this medication. It works by helping the body produce an enzyme called alpha-galactosidase A, which is deficient in people with Fabry disease.
Related Terms
- Fabry disease: A rare genetic disorder that results from the buildup of a particular type of fat, called globotriaosylceramide, in the body's cells.
- Pharmacological chaperone: A small molecule that binds to and stabilizes a protein, helping it to fold and function correctly.
- Alpha-galactosidase A: An enzyme that breaks down certain fats in the body. Deficiency of this enzyme leads to Fabry disease.
See Also
- Enzyme replacement therapy: A medical treatment for some diseases caused by the deficiency or absence of a specific enzyme in the body.
- Genetic disorder: A disease caused by abnormalities in an individual's genetic material.
External links
- Medical encyclopedia article on Migalastat
- Wikipedia's article - Migalastat
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski